BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22384257)

  • 1. EGFR kinase promotes acquisition of stem cell-like properties: a potential therapeutic target in head and neck squamous cell carcinoma stem cells.
    Abhold EL; Kiang A; Rahimy E; Kuo SZ; Wang-Rodriguez J; Lopez JP; Blair KJ; Yu MA; Haas M; Brumund KT; Altuna X; Patel A; Weisman RA; Ongkeko WM
    PLoS One; 2012; 7(2):e32459. PubMed ID: 22384257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A CD44high/EGFRlow subpopulation within head and neck cancer cell lines shows an epithelial-mesenchymal transition phenotype and resistance to treatment.
    La Fleur L; Johansson AC; Roberg K
    PLoS One; 2012; 7(9):e44071. PubMed ID: 23049743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD44(high) /ALDH1(high) head and neck squamous cell carcinoma cells exhibit mesenchymal characteristics and GSK3β-dependent cancer stem cell properties.
    Seino S; Shigeishi H; Hashikata M; Higashikawa K; Tobiume K; Uetsuki R; Ishida Y; Sasaki K; Naruse T; Rahman MZ; Ono S; Simasue H; Ohta K; Sugiyama M; Takechi M
    J Oral Pathol Med; 2016 Mar; 45(3):180-8. PubMed ID: 26399460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma.
    Hoeben A; Martin D; Clement PM; Cools J; Gutkind JS
    Int J Cancer; 2013 Mar; 132(5):1042-50. PubMed ID: 22865653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
    Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM
    Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.
    Kalish LH; Kwong RA; Cole IE; Gallagher RM; Sutherland RL; Musgrove EA
    Clin Cancer Res; 2004 Nov; 10(22):7764-74. PubMed ID: 15570011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.
    Bourguignon LY; Wong G; Earle C; Chen L
    J Biol Chem; 2012 Sep; 287(39):32800-24. PubMed ID: 22847005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer.
    Pernas FG; Allen CT; Winters ME; Yan B; Friedman J; Dabir B; Saigal K; Mundinger GS; Xu X; Morris JC; Calvo KR; Van Waes C; Chen Z
    Clin Cancer Res; 2009 Apr; 15(7):2361-72. PubMed ID: 19318490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosteric modulation by protein kinase Cε leads to modified responses of EGF receptor towards tyrosine kinase inhibitors.
    Weisheit S; Liebmann C
    Cell Signal; 2012 Feb; 24(2):422-434. PubMed ID: 21964064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer.
    Nör C; Zhang Z; Warner KA; Bernardi L; Visioli F; Helman JI; Roesler R; Nör JE
    Neoplasia; 2014 Feb; 16(2):137-46. PubMed ID: 24709421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel C-Terminal Heat Shock Protein 90 Inhibitors (KU711 and Ku757) Are Effective in Targeting Head and Neck Squamous Cell Carcinoma Cancer Stem cells.
    Subramanian C; Kovatch KJ; Sim MW; Wang G; Prince ME; Carey TE; Davis R; Blagg BSJ; Cohen MS
    Neoplasia; 2017 Dec; 19(12):1003-1011. PubMed ID: 29121598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.
    Jameson MJ; Beckler AD; Taniguchi LE; Allak A; Vanwagner LB; Lee NG; Thomsen WC; Hubbard MA; Thomas CY
    Mol Cancer Ther; 2011 Nov; 10(11):2124-34. PubMed ID: 21878657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitor of DNA binding 2 is a novel therapeutic target for stemness of head and neck squamous cell carcinoma.
    Bae WJ; Koo BS; Lee SH; Kim JM; Rho YS; Lim JY; Moon JH; Cho JH; Lim YC
    Br J Cancer; 2017 Dec; 117(12):1810-1818. PubMed ID: 29096401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.
    Keysar SB; Le PN; Miller B; Jackson BC; Eagles JR; Nieto C; Kim J; Tang B; Glogowska MJ; Morton JJ; Padilla-Just N; Gomez K; Warnock E; Reisinger J; Arcaroli JJ; Messersmith WA; Wakefield LM; Gao D; Tan AC; Serracino H; Vasiliou V; Roop DR; Wang XJ; Jimeno A
    J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27634934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting cancer stem cell plasticity through modulation of epidermal growth factor and insulin-like growth factor receptor signaling in head and neck squamous cell cancer.
    Leong HS; Chong FT; Sew PH; Lau DP; Wong BH; Teh BT; Tan DS; Iyer NG
    Stem Cells Transl Med; 2014 Sep; 3(9):1055-65. PubMed ID: 25024430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell.
    Lim YC; Kang HJ; Moon JH
    Oral Oncol; 2014 Jul; 50(7):633-9. PubMed ID: 24835851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells.
    Yang Z; Bagheri-Yarmand R; Wang RA; Adam L; Papadimitrakopoulou VV; Clayman GL; El-Naggar A; Lotan R; Barnes CJ; Hong WK; Kumar R
    Clin Cancer Res; 2004 Jan; 10(2):658-67. PubMed ID: 14760089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR regulates the side population in head and neck squamous cell carcinoma.
    Chen JS; Pardo FS; Wang-Rodriguez J; Chu TS; Lopez JP; Aguilera J; Altuna X; Weisman RA; Ongkeko WM
    Laryngoscope; 2006 Mar; 116(3):401-6. PubMed ID: 16540898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Slug is a novel molecular target for head and neck squamous cell carcinoma stem-like cells.
    Moon JH; Lee SH; Koo BS; Kim JM; Huang S; Cho JH; Eun YG; Shin HA; Lim YC
    Oral Oncol; 2020 Dec; 111():104948. PubMed ID: 32771963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.